NCT01814826View on ClinicalTrials.gov

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 10, 2013

Primary Completion Date

May 3, 2016

Study Completion Date

April 8, 2018

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

MLN4924

"MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles"

DRUG

Azacitidine

"Azacitidine (IV) or subcutaneously in AML participants in a 28-day cycle:~\- Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles"

Trial Locations (8)

27599

UNC-Chapel Hill School of Medicine, Chapel Hill

32224

Mayo Clinic - Jacksonville, FL, Jacksonville

33136

University of Miami School of Medicine, Miami

35294

University of Alabama at Birmingham, Birmingham

37203

Sarah Cannon Research Institute, Nashville

78229

Methodist Hospital, San Antonio

80218

Hospital Corporation of America-HealthOne, LLC, Denver

94305-5826

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT01814826 - Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | Biotech Hunter | Biotech Hunter